
Quarterly ResultNov 3, 2026, 08:12 AM
Teva Q3 Revenue $4.4B; Innovative Brands Up 33%; Raises Outlook
AI Summary
Teva Pharmaceutical Industries Ltd. announced its third-quarter 2026 financial results, reporting $4.4 billion in revenue, a 2% decrease year-over-year, primarily due to lower global generics revenues. However, the company saw significant growth in its key innovative brands, which collectively increased by 33% to $1.1 billion. Teva also reported substantial gross margin expansion, with non-GAAP gross profit margin reaching 58.7%. The company raised its 2026 revenue outlook for AUSTEDO®, AJOVY®, and UZEDY® and announced strategic developments including the U.S. launch of WELTRUZA™ and the acquisition of BXCL-501.
Key Highlights
- Teva reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year.
- Non-GAAP gross profit margin increased to 58.7%, the highest in a decade.
- Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 33% year-over-year, reaching $1.1 billion.
- AUSTEDO global revenues were $751 million (+21% YoY), AJOVY $269 million (+61% YoY), UZEDY $85 million (+96% YoY).
- Teva raised 2026 revenue outlook for AUSTEDO, AJOVY, and UZEDY.
- Launched WELTRUZA™ for schizophrenia treatment in the U.S.
- Acquired BXCL-501 for agitation associated with schizophrenia or bipolar disorder.
- Strengthened biosimilars collaboration with Samsung Bioepis.
Price Impact
More from TEVA